Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QTRX 
Quanterix Corp (QTRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: QTRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.25
1 Year Target Price $11.25
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.42% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 258.39M USD | Price to earnings Ratio - | 1Y Target Price 11.25 |
Price to earnings Ratio - | 1Y Target Price 11.25 | ||
Volume (30-day avg) 4 | Beta 1.05 | 52 Weeks Range 4.05 - 16.74 | Updated Date 06/30/2025 |
52 Weeks Range 4.05 - 16.74 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -35.28% | Operating Margin (TTM) -86.92% |
Management Effectiveness
Return on Assets (TTM) -9.38% | Return on Equity (TTM) -14.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27914945 | Price to Sales(TTM) 1.9 |
Enterprise Value 27914945 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 0.21 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 38854900 | Shares Floating 30014339 |
Shares Outstanding 38854900 | Shares Floating 30014339 | ||
Percent Insiders 7.66 | Percent Institutions 89.7 |
Analyst Ratings
Rating 2 | Target Price 11.25 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quanterix Corp
Company Overview
History and Background
Quanterix Corp was founded in 2007 and went public in 2017. It focuses on developing ultra-sensitive single molecule detection technology for human health. Initially developed at Tufts University, it aims to revolutionize diagnostics and drug development.
Core Business Areas
- Simoa Technology: This segment develops and markets the Simoa platform, which is an ultra-sensitive immunoassay technology used for biomarker detection in blood, serum, plasma, and other fluids. It helps in early disease detection, diagnosis, prognosis, and therapeutic development. Revenue from this segment makes up the bulk of the company's sales.
- Accelerator Laboratory Services: This is the company's service business, offering biomarker testing services to pharmaceutical and biotechnology companies, academic researchers, and other organizations. This service complements the Simoa instrument and assay sales.
Leadership and Structure
The leadership team includes Masoud Toloue, Ph.D. as Chief Executive Officer. The organizational structure is function-based, encompassing research and development, manufacturing, commercial operations, and administrative departments. Board of Directors is the top of the structure.
Top Products and Market Share
Key Offerings
- Simoa Platform: The Simoa platform is Quanterix's flagship product, enabling ultra-sensitive detection of biomarkers. This platform helps detect diseases earlier than traditional immunoassay methods. The platform includes Simoa HD-X Analyzer, Simoa SR-X Analyzer, and Simoa bead-based assays. The competitor for this product are companies providing ELISA-based assays and other immunoassay platforms.
- Accelerator Laboratory Services: Quanterix's Accelerator Lab provides biomarker testing services, utilizing the Simoa technology. It allows customers to outsource biomarker analysis, gaining access to high-sensitivity testing without investing in equipment or expertise. Competitors include CROs and other biomarker testing labs.
Market Dynamics
Industry Overview
The diagnostics and biomarker analysis market is experiencing significant growth due to the increasing prevalence of chronic diseases, advances in technology, and growing demand for personalized medicine. The market is highly competitive and regulated.
Positioning
Quanterix is positioned as a leader in ultra-sensitive biomarker detection. Its Simoa technology offers a competitive advantage in applications requiring high sensitivity, such as early disease detection and drug development. They are a niche player but have a strong moat in certain ultra-sensitive detection niches.
Total Addressable Market (TAM)
The TAM for biomarker analysis is expected to reach over $50 billion in the next few years. Quanterix is positioned to capture a significant share of this market, especially in ultra-sensitive applications. The company is aggressively expanding its product offerings to capitalize on this growing opportunity.
Upturn SWOT Analysis
Strengths
- Proprietary Simoa technology offering ultra-high sensitivity
- Established relationships with pharmaceutical and biotechnology companies
- Strong brand recognition in the biomarker analysis market
- Expertise in biomarker assay development and manufacturing
Weaknesses
- High cost of Simoa instruments and assays
- Limited market adoption compared to traditional immunoassays
- Dependency on key opinion leaders and early adopters
- Historical unprofitability
Opportunities
- Expanding applications of Simoa technology in neurology, oncology, and infectious diseases
- Partnerships with pharmaceutical companies for drug development and clinical trials
- Increasing demand for biomarker testing in personalized medicine
- Geographic expansion into emerging markets
Threats
- Competition from established immunoassay vendors
- Technological advancements that could render Simoa technology obsolete
- Regulatory hurdles and reimbursement challenges
- Economic downturn affecting research and development spending
Competitors and Market Share
Key Competitors
- ILMN
- DHCN
- TMO
Competitive Landscape
Quanterix has a strong advantage in ultra-sensitive biomarker detection due to its proprietary Simoa technology. However, it faces competition from larger players with broader product portfolios and established customer bases. The company's success depends on its ability to demonstrate the clinical and economic value of Simoa technology.
Major Acquisitions
UmanDiagnostics
- Year: 2021
- Acquisition Price (USD millions): 52.5
- Strategic Rationale: Expanded neurology biomarker portfolio, adding expertise in neurofilament light chain (NfL) measurement. Increased Simoa test menu offerings.
Growth Trajectory and Initiatives
Historical Growth: Quanterix has experienced rapid revenue growth in recent years, driven by increased adoption of Simoa technology. Historical growth is in double-digit percentages YoY.
Future Projections: Analyst estimates suggest continued revenue growth for Quanterix, driven by expanding applications of Simoa technology. Analysts' projections varies depending on the source and model used.
Recent Initiatives: Recent initiatives include launching new Simoa assays, expanding the Accelerator Lab service offerings, and forging strategic partnerships with pharmaceutical companies. They are also focusing on automation of their instruments.
Summary
Quanterix is a specialized company with a strong technology, Simoa, but faces challenges in market adoption due to its cost. The company is experiencing rapid growth and faces competition from larger players. Its success hinges on expanding the applications of Simoa and forming strategic partnerships. They need to increase margins and control expenses to achieve profitability. Quanterix needs to monitor advancements in competing technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Quanterix Investor Relations
- Analyst Reports
- Company SEC Filings
- Industry Research Reports
- FactSet
- MarketWatch
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary. Financial data may be outdated. Always conduct thorough research and consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quanterix Corp
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2017-12-07 | President, CEO & Director Dr. Masoud Toloue Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 471 | Website https://www.quanterix.com |
Full time employees 471 | Website https://www.quanterix.com | ||
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.